Off-label use of cinacalcet in pediatric primary hyperparathyroidism: a French multicenter experience

Background: Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience...

Full description

Saved in:
Bibliographic Details
Main Authors: Bernardor, Julie (Author) , Flammier, Sacha (Author) , Salles, Jean-Pierre (Author) , Amouroux, Cyril (Author) , Castanet, Mireille (Author) , Lienhardt, Anne (Author) , Martinerie, Laetitia (Author) , Damgov, Ivan (Author) , Linglart, Agnès (Author) , Bacchetta, Justine (Author)
Format: Article (Journal)
Language:English
Published: 24 August 2022
In: Frontiers in Pediatrics
Year: 2022, Volume: 10, Pages: 1-17
ISSN:2296-2360
DOI:10.3389/fped.2022.926986
Online Access:Verlag, Volltext: http://dx.doi.org/10.3389/fped.2022.926986
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fped.2022.926986
Get full text
Author Notes:Julie Bernardor, Sacha Flammier, Jean-Pierre Salles, Cyril Amouroux, Mireille Castanet, Anne Lienhardt, Laetitia Martinerie, Ivan Damgov, Agnès Linglart and Justine Bacchetta

MARC

LEADER 00000caa a2200000 c 4500
001 1822648165
003 DE-627
005 20230427160535.0
007 cr uuu---uuuuu
008 221116s2022 xx |||||o 00| ||eng c
024 7 |a 10.3389/fped.2022.926986  |2 doi 
035 |a (DE-627)1822648165 
035 |a (DE-599)KXP1822648165 
035 |a (OCoLC)1361670581 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bernardor, Julie  |e VerfasserIn  |0 (DE-588)1272890228  |0 (DE-627)1822648831  |4 aut 
245 1 0 |a Off-label use of cinacalcet in pediatric primary hyperparathyroidism  |b a French multicenter experience  |c Julie Bernardor, Sacha Flammier, Jean-Pierre Salles, Cyril Amouroux, Mireille Castanet, Anne Lienhardt, Laetitia Martinerie, Ivan Damgov, Agnès Linglart and Justine Bacchetta 
264 1 |c 24 August 2022 
300 |b Diagramme 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 16.11.2022 
520 |a Background: Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience in this setting.MethodsWe retrospectively analyzed data from 18 pediatric patients from 7 tertiary centers who received cinacalcet for PHPT. The results are presented as median (interquartile range).ResultsAt a median age of 10.8 (2.0-14.4) years, 18 patients received cinacalcet for primary HPT (N = 13 inactive CASR mutation, N = 1 CDC73 mutation, N = 1 multiple endocrine neoplasia type 1, N=3 unknown etiology). Cinacalcet was introduced at an estimated glomerular filtration rate (eGFR) of 120 (111-130) mL/min/1.73 m2, plasma calcium of 3.04 (2.96-3.14) mmol/L, plasma phosphate of 1.1 (1.0-1.3) mmol/L, age-standardized (z score) phosphate of −3.0 (−3.5;−1.9), total ALP of 212 (164-245) UI/L, 25-OHD of 37 (20-46) ng/L, age-standardized (z score) ALP of −2.4 (−3.7;−1.4), PTH of 75 (59-123) ng/L corresponding to 1.2 (1.0-2.3)-time the upper limit for normal (ULN). The starting daily dose of cinacalcet was 0.7 (0.6-1.0) mg/kg, with a maximum dose of 1.0 (0.9-1.4) mg/kg per day. With a follow-up of 2.2 (1.3-4.3) years on cinacalcet therapy, PTH and calcium significantly decreased to 37 (34-54) ng/L, corresponding to 0.8 (0.5-0.8) ULN (p = 0.01), and 2.66 (2.55-2.90) mmol/L (p = 0.002), respectively. In contrast, eGFR, 25-OHD, ALP and phosphate and urinary calcium levels remained stable. Nephrocalcinosis was not reported but one patient displayed nephrolithiasis. Cinacalcet was progressively withdrawn in three patients; no side effects were reported.ConclusionsCinacalcet in pediatric HPT can control hypercalcemia and PTH without significant side effects. 
700 1 |a Flammier, Sacha  |e VerfasserIn  |4 aut 
700 1 |a Salles, Jean-Pierre  |e VerfasserIn  |4 aut 
700 1 |a Amouroux, Cyril  |e VerfasserIn  |4 aut 
700 1 |a Castanet, Mireille  |e VerfasserIn  |4 aut 
700 1 |a Lienhardt, Anne  |e VerfasserIn  |4 aut 
700 1 |a Martinerie, Laetitia  |e VerfasserIn  |4 aut 
700 1 |a Damgov, Ivan  |d 1992-  |e VerfasserIn  |0 (DE-588)1239075308  |0 (DE-627)1767106246  |4 aut 
700 1 |a Linglart, Agnès  |e VerfasserIn  |4 aut 
700 1 |a Bacchetta, Justine  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in Pediatrics  |d Lausanne : Frontiers Media, 2013  |g 10(2022) vom: Aug., Seite 1-17  |h Online-Ressource  |w (DE-627)742738744  |w (DE-600)2711999-3  |w (DE-576)381569756  |x 2296-2360  |7 nnas  |a Off-label use of cinacalcet in pediatric primary hyperparathyroidism a French multicenter experience 
773 1 8 |g volume:10  |g year:2022  |g month:08  |g pages:1-17  |g extent:17  |a Off-label use of cinacalcet in pediatric primary hyperparathyroidism a French multicenter experience 
856 4 0 |u http://dx.doi.org/10.3389/fped.2022.926986  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fped.2022.926986  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221116 
993 |a Article 
994 |a 2022 
998 |g 1239075308  |a Damgov, Ivan  |m 1239075308:Damgov, Ivan  |d 910000  |d 910500  |e 910000PD1239075308  |e 910500PD1239075308  |k 0/910000/  |k 1/910000/910500/  |p 8 
999 |a KXP-PPN1822648165  |e 421229995X 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"24 August 2022","dateIssuedKey":"2022"}],"relHost":[{"titleAlt":[{"title":"FPED"}],"title":[{"title":"Frontiers in Pediatrics","title_sort":"Frontiers in Pediatrics"}],"disp":"Off-label use of cinacalcet in pediatric primary hyperparathyroidism a French multicenter experienceFrontiers in Pediatrics","id":{"issn":["2296-2360"],"zdb":["2711999-3"],"eki":["742738744"]},"recId":"742738744","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 04.06.20"],"part":{"volume":"10","pages":"1-17","extent":"17","text":"10(2022) vom: Aug., Seite 1-17","year":"2022"},"origin":[{"publisherPlace":"Lausanne","dateIssuedDisp":"2013-","dateIssuedKey":"2013","publisher":"Frontiers Media"}],"pubHistory":["2013 -"]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 16.11.2022"],"physDesc":[{"extent":"17 S.","noteIll":"Diagramme"}],"language":["eng"],"recId":"1822648165","id":{"eki":["1822648165"],"doi":["10.3389/fped.2022.926986"]},"person":[{"roleDisplay":"VerfasserIn","role":"aut","family":"Bernardor","given":"Julie","display":"Bernardor, Julie"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Flammier","given":"Sacha","display":"Flammier, Sacha"},{"family":"Salles","roleDisplay":"VerfasserIn","role":"aut","display":"Salles, Jean-Pierre","given":"Jean-Pierre"},{"display":"Amouroux, Cyril","given":"Cyril","role":"aut","roleDisplay":"VerfasserIn","family":"Amouroux"},{"given":"Mireille","display":"Castanet, Mireille","roleDisplay":"VerfasserIn","role":"aut","family":"Castanet"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Lienhardt","display":"Lienhardt, Anne","given":"Anne"},{"given":"Laetitia","display":"Martinerie, Laetitia","role":"aut","roleDisplay":"VerfasserIn","family":"Martinerie"},{"display":"Damgov, Ivan","given":"Ivan","role":"aut","roleDisplay":"VerfasserIn","family":"Damgov"},{"roleDisplay":"VerfasserIn","role":"aut","family":"Linglart","display":"Linglart, Agnès","given":"Agnès"},{"display":"Bacchetta, Justine","given":"Justine","family":"Bacchetta","role":"aut","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Off-label use of cinacalcet in pediatric primary hyperparathyroidism","subtitle":"a French multicenter experience","title":"Off-label use of cinacalcet in pediatric primary hyperparathyroidism"}],"name":{"displayForm":["Julie Bernardor, Sacha Flammier, Jean-Pierre Salles, Cyril Amouroux, Mireille Castanet, Anne Lienhardt, Laetitia Martinerie, Ivan Damgov, Agnès Linglart and Justine Bacchetta"]}} 
SRT |a BERNARDORJOFFLABELUS2420